Was Maimonides a proto-clinical pharmacologist?

Aim: To determine whether the defining stance of clinical pharmacology—the critical appraisal and rational application of an inherited evidence base, as distinct from the discovery of drugs—is present in the medical writings of Maimonides (1138–1204), and to place him historically without anachronism or hagiography. Methods: In this context, clinical pharmacology—or an early form of it (“proto-clinical pharmacology”)—was considered as a method or stance, operationalised as a set of constitutive operations: critical appraisal of received evidence; specification of dose, route and preparation; formulary design for the conditions of real-world use; explicit risk-benefit assessment, with attention to iatrogenic injury; individualisation; and transmission. Maimonides’ corpus, in Gerrit Bos’ critical Arabic editions[1–18](#ref-0001), was interrogated against each operation, within the physicians’ own 12th-century category of al-juzʾ al-ʿamalī—the “practical part” of medicine, which Avicenna held to be itself a science of application. Absence and error were recorded as carefully as presence. Results: The stance is present across the corpus and stated in the open: a reported negative drug trial; dissent from unanimous consensus for want of warrant; rule-governed dosing with named covariates (age, climate, symptom severity, individual temperament); explicit therapeutic-window reasoning; iatrogenic harm named as the central hazard of the art; and individualisation as the genre of an entire treatise. It is met unevenly; empirical evaluation is the weakest criterion. While the stance was inherited from an Andalusian lineage (the multi-generation Ban Zūhr family of physicians and Averroes)—of which Maimonides is the reflexive, systematising node rather than the origin—it did not propagate downstream as such. His students and the Hebrew, Latin and Arabic receptions transmitted content, not critical method. Conclusion: Maimonides was a proto-clinical pharmacologist: the reflexive high-water mark of an inherited critical bedside pharmacology, embedded in a humoral science that is not ours. Modern clinical pharmacology shares his stance by convergence, not descent.